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Abstract: Despite signiﬁ  cant advancement in the diagnosis and treatment of breast cancer, many patients succumb to this 
disease. The elucidation of aberrant signaling pathways that lead to breast cancer should help develop more effective 
therapeutic strategies. The Akt signaling pathway plays an important role in the development and progression of breast 
cancer. Overexpression/activation of Akt has been associated with poor prognosis and resistance to hormonal and 
chemotherapy. Although mutations in Akt are rare in breast cancer, the activity of Akt is regulated by hormones, growth 
factors, growth factor receptors, oncogenes and tumor suppressor genes that are often deregulated in breast cancer. The 
objective of this commentary is to discuss recent literature on how activation of Akt by various signaling pathways contributes 
to breast cancer and confers resistance to current therapy.
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Introduction
One in four women is diagnosed with breast cancer, which is the second leading cause of cancer-related 
death in women in the United States. Current treatment options include surgery, radiation and systemic 
therapy (e.g. hormonal therapy, chemotherapy and biological therapy). Major problems with chemo-
therapy are toxic side effects and emergence of drug resistance. The development of rational therapeutic 
approaches for breast cancer requires an understanding of the cellular signaling pathways leading to 
breast cancer. Since estrogen promotes growth of breast cancer and 70% of breast cancer patients are 
estrogen receptor (ER)-positive, antiestrogens (e.g. tamoxifen) are frequently used to treat patients 
with breast cancer. Fulvestrant, a novel ER antagonist that degrades ER, is more effective than tamoxifen 
(Raina, 2004). Aromatase inhibitors (e.g. letrozole, anastrozole and exemestane), which inhibit estrogen 
synthesis, are now in use to treat postmenopausal women with breast cancer. The use of antiestrogens 
and aromatase inhibitors is, however, recommended for hormone receptor-positive breast tumors. In 
addition, inherent and acquired resistance to endocrine therapy is a signiﬁ  cant problem (Gururaj et al. 
2006).
The human epidermal growth factor receptor (EGFR) or HER family of proteins comprised of EGFR 
(HER1), HER2, HER3 and HER4 are type 1 tyrosine kinase growth factor receptors (Arteaga, 2003; 
Gullick and Srinivasan, 1998). HER2 gene is ampliﬁ  ed or overexpressed in up to 25% of patients with 
breast cancer (Slamon et al. 1987). It can contribute to both development of breast cancer and its pro-
gression to aggressive forms. Herceptin (trastuzumab), a humanized monoclonal antibody against 
HER2/neu, was the ﬁ  rst HER-2-targeted biologic agent approved for the therapy of breast cancer 
(Fig. 1). Although trastuzumab improved the survival of patients with HER2-positive metastatic breast 
cancers, especially when combined with chemotherapy, the development of resistance to trastuzumab 
and its high cost restrict its therapeutic use. Several small molecule inhibitors that target EGFR tyrosine 
kinase activity, (e.g. erlotinib, geﬁ  tinib, lapatinib and canertinib), farnesyl transferase inhibitors that 
target Ras, and rapamycin and its analogues that inhibit mammalian target of rapamycin (mTOR) have 
been developed (Fig. 1). These compounds show limited success as a single agent but they are more 
effective when combined with trastuzumab, antiestrogens or aromatase inhibitors (Gligorov et al. 2007; 
Goss and Wu, 2007).
The development of successful therapeutic agents requires not only identiﬁ  cation of appropriate 
molecular targets but also elucidation of the signaling pathways that may contribute to resistance to 12
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these agents. The Akt/protein kinase B (PKB) serine/
threonine kinase regulates a myriad of cellular 
processes, including metabolism, cell proliferation, 
cell survival and cell growth (Vivanco and Saw-
yers, 2002). It mediates its multiple functions by 
phosphorylating a large number of substrates, 
including glycogen synthase kinase-3, cyclin D1, 
cyclin-dependent kinase inhibitors (p27 and p21), 
caspase-9, Bad, MDM2 and forkhead transcription 
factors (Woodgett, 2005; Liu et al. 2007; Vivanco 
and Sawyers, 2002). Activation of Akt has been 
associated with up to 40% of breast cancers (Liu 
et al. 2007). The increase in phospho-Akt level in 
breast tumor samples correlates with poor progno-
sis (Stal et al. 2003; Tokunaga et al. 2006; Zhou 
et al. 2004) and predicts a worse outcome among 
endocrine-treated patients (Perez-Tenorio, 2002). 
Akt has been associated with tumor progression, 
invasion, metastasis, and resistance to hormonal 
and chemotherapy (DeGraffenried et al. 2003; 
Faridi et al. 2003; Liu et al. 2007; Qiao et al. 2007; 
Sale and Sale, 2007; Zhao et al. 2007). Thus, Akt 
is an important therapeutic target for the treatment 
of breast cancer. This commentary discusses how 
deregulation in various signaling pathways con-
tributes to breast cancer via activation of the Akt 
signaling pathway.
Activation of Akt
Although many breast tumors exhibit an increase 
in constitutively-active Akt, mutations in Akt are 
rare, suggesting that the elevated Akt activity 
results from an alteration of regulators of Akt 
rather than any mutation (Sun, 2001b). Akt 
is activated by a variety of growth factors, includ-
ing insulin, insulin-like growth factor-1 and epi-
dermal growth factor (Sale and Sale, 2007). It 
acts downstream of phosphoinositide-3 kinase 
(PI3K) and mediates the survival effects of differ-
ent growth factors, cytokines and oncogenes 
(Hemmings, 1997). Activation of PI3K generates 
3-phosphoinositides that bind to the pleckstrin 
homology (PH) domain of Akt inducing its mem-
brane translocation and conformational change 
required for its phosphorylation and activation 
(Galetic, 1999). Phosphorylation appears to be 
critical for its kinase activity (Chan, 1999; Galetic, 
1999). Akt is phosphorylated at Thr308 in the 
activation loop by phosphoinositide-dependent 
protein kinase 1 (PDK1) (Alessi et al. 1997, 
Williams et al. 2000). Phosphorylation of Akt at 
the Ser473 site in the carboxy terminal domain is 
necessary for its full activation. Several kinases, 
including PDK1, integrin-linked kinase (ILK) 
(Delcommenne et al. 1998; Troussard et al. 2003), 
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rictor-mTOR complex (Sarbassov et al. 2005), 
mitogen-activated protein kinase-activated protein 
kinase 2 (MAPKAP kinase-2) (Alessi et al. 1996; 
Rane, 2001) and DNA-dependent protein kinase 
(DNA-PK) (Feng et al. 2004) have been impli-
cated in phosphorylating the Ser473 site in Akt.
The Involvement of Akt Isoforms 
in Breast Cancer
Three isoforms of Akt have been identiﬁ  ed: Akt1/
PKBα, Akt2/PKBβ and Akt3/PKBγ (Manning and 
Cantley, 2007). Akt1 is the most abundant isoform. 
All three Akt isoforms have been associated with 
breast cancer (Bacus et al. 2002; Bellacosa et al. 
1995; Nakatani et al. 1999; Perez-Tenorio and Stal, 
2002; Stal et al. 2003; Sun et al. 2001a; Sun et al. 
2001b; Faridi et al. 2003; Ju et al. 2007). Akt1 is 
overexpressed in breast cancer cells and has been 
shown to be important in estrogen-stimulated 
growth (Ahmad et al. 1999; Stal et al. 2003). It 
has been reported that Akt2 is ampliﬁ  ed in 3% of 
breast cancers (Bellacosa, 1995) and is frequently 
activated in primary human breast carcinoma 
(Sun, 2001a). Akt1 and Akt2 have opposite role 
in invasion and metastasis. While Akt1 inhibits 
invasion, metastasis and epithelial to mesenchy-
mal transition (EMT), Akt2 facilitates cell migra-
tion and EMT (Irie et al. 2005; Toker and 
Yoeli-Lerner, 2006). A recent report suggests that 
Akt2 contributes to breast cancer metastasis via 
protein kinase C (PKC)-ζ (Wang et al. 2008). 
Upregulation of Akt3 may contribute to the more 
aggressive clinical phenotype of the ER-negative 
breast cancers (Nakatani K, 1999) although one 
report showed Akt3 mRNA expression is not 
restricted to tumorigenic cell lines or to ER-nega-
tive breast cancer cells (Zinda, 2001). However, 
transfection of constitutively active Akt-3 in 
MCF-7 cells reversed estrogen and tamoxifen 
response of MCF-7 cells (Faridi et al. 2003). Thus, 
an understanding of the distinct role of Akt iso-
forms is essential to exploit the Akt signaling 
pathway for breast cancer therapy.
Akt Takes Center Stage
Several signaling pathways that are deregulated 
in breast cancer act via the Akt signaling 
pathway. Akt is often activated in breast tumors 
overexpressing HER2 (Tokunaga et al. 2006). It 
has been reported that HER2 mediates its 
oncogenic signaling via the PI3K/Akt signaling 
pathway (Hsieh and Moasser, 2007). Although 
HER2 does not directly bind to and activate 
PI3K/Akt, it activates Akt through tyrosine 
phosphorylation of HER3 (Soltoff et al. 1994). 
HER2 forms heterodimers with HER3 and 
transphosphorylation of HER3 by HER2 allows 
HER3 to interact with the p85 regulatory subunit 
of PI3K (Fig. 1), thereby causing activation of 
PI3K/Akt (Soltoff et al. 1994). It has been shown 
that the p85 regulatory subunit of PI3K can also 
interact with ERα causing activation of Akt 
(Simoncini et al. 2000). Furthermore, PI3K can 
cause phosphorylation and activation of ER. Thus, 
a combination of PI3K/Akt inhibitors with 
trastuzumab, tyrosine kinase inhibitors and 
antiestrogens may be more effective in treating 
breast cancer compared to a single agent.
Since Akt activity is regulated by phosphoryla-
tion at the Ser473 site, a deregulation in kinases 
and phosphatases that regulate phosphorylation at 
this site can result in activation of Akt. Integrin-
linked kinase (ILK) has been shown to phosphor-
ylate Akt at the S473 site although it is not clear if 
ILK directly phosphorylates Akt or if it acts as a 
scaffolding protein allowing another kinase to 
phosphorylate Akt (Hinton et al. 2008). Recently, 
it has been reported that a rictor/ILK complex 
regulates phosphorylation of Akt at Ser473 
(McDonald et al. 2008). ILK has been associated 
with breast cancer progression and metastasis 
through Akt activation (Hinton et al. 2008).
The tumor suppressor protein phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) 
that dephosphorylates the 3 position of phos-
phoinositides and thereby inactivates Akt is also 
deregulated in breast carcinoma (Cantley, 1999). 
Although mutations in PTEN have been detected 
in a small percentage of breast cancers, loss of 
heterozygosity (LOH) at the PTEN locus is a more 
common occurrence in breast cancer (Haiman 
et al. 2006). The reduced expression of PTEN 
protein was found in 30% of breast cancers and 
correlated with lymph node metastases and a worse 
prognosis (Tsutsui et al. 2005). The PH domain/
leucin-rich repeat protein phosphatase (PHLPP) 
that directly dephosphorylates Ser473 in Akt and 
thereby inactivates it has recently been identiﬁ  ed 
(Gao et al. 2005). A decrease in the expression of 
PHLPP was associated with progression to metas-
tasis in a series of human epithelial cells obtained 
by successive biopsies from one breast cancer 
patient (Qiao et al. 2007).14
Basu
Breast Cancer: Basic and Clinical Research 2008:2 
Akt can act both upstream and downstream of 
mammalian target of rapamycin (mTOR) which 
regulates protein translation and cell cycle progres-
sion via its downstream effectors p70 S6 kinase 
(p70S6K) and 4E-binding protein-1 (Fig. 1). 
mTOR can form a complex with either raptor or 
rictor to form mTORC1 or mTORC2, respectively 
(Sarbassov et al. 2005). mTORC1, but not 
mTORC2, is rapamycin sensitive. Akt can activate 
mTOR by phosphorylating and inactivating the 
tumor suppressor protein tubersclerosis complex 
2 (TSC2), which negatively regulates mTOR activ-
ity. Furthermore, persistent activation of p70S6K 
can lead to feedback inhibition of the PI3K/Akt 
pathway (O’Reilly et al. 2006). mTOR is critical 
for the proliferative responses mediated by growth 
factor receptors (Mita et al. 2003) and is required 
for estrogen-induced breast tumor cell proliferation 
(Boulay et al. 2005). Constitutive signaling through 
this pathway is a cause of treatment failure in breast 
cancer patients (Crowder and Ellis, 2005). Rapa-
mycin and its analogues, such as temsirolimus 
(CCI-779) and everolimus (RAD-001) are in 
clinical trials (Fig. 1). Breast cancer cells with 
activated Akt are exquisitely sensitive to mTOR 
antagonists (Yu et al. 2001). Activation of Akt/
mTOR pathway can cause resistance to tamoxifen 
(Clark et al. 2002). Combination of mTOR antag-
onists with antiestrogens and aromatase inhibitors 
has been effective in treating hormone-sensitive 
breast cancers (deGraffenried et al. 2004). A recent 
study showed that mutation perturbing the lipid 
and protein phosphatase activities of PTEN caused 
activation of Akt/mTOR/p70S6K signaling and 
chemoresistance, whereas rapamycin synergized 
with doxorubicin to inhibit growth of breast cancer 
cells (Steelman et al. 2008).
Conclusion
The signaling pathways that are altered in breast 
cancer or in response to therapy can greatly 
inﬂ  uence clinical outcome. The development of 
molecular-targeted therapies presents promises as 
well as challenges. The PI3K/Akt signaling pathway 
has received considerable attention because of its 
critical role in the development and progression of 
breast cancer. In addition, the status of Akt can 
inﬂ  uence both inherent and acquired resistance to 
systemic therapy. In targeting the Akt pathway, one 
must consider that different Akt isoforms may have 
redundant, distinct or opposite functions. In 
addition, the status of different signaling pathways 
that feed into the Akt signaling pathway may have 
a signiﬁ  cant impact on patient response to therapy. 
Thus, while combining inhibitors of the PI3K/Akt 
pathway in conjunction with currently available 
therapeutic agents may greatly improve their 
efficacy, finding the right combination is the 
challenge.
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